While its net profit, revenue and earnings before interest and tax depreciation and amortization (EBITDA) have increased, its margins have contracted.
Rossari Biotech’s net profit rose 3.2 per cent to ₹32.7 crore from ₹31.7 crore in the previous year.
Its revenue saw an increase of 13.4 per cent to ₹581.6 crore from ₹512.7 crore in the third quarter of the previous fiscal.
The company’s EBITDA also grew 6.3% annually from ₹64.7 crore to ₹68.8 crore.
However, its margin contracted to 11.8%, compared to 12.6% a year earlier.
Shares of Rossari Biotech ended the previous session down almost 1% at ₹534.5 apiece. The stock is down 33.6% over the past year.
Also Read: Punjab and Sind Bank Q3 Results | Profit increases by 19% year-on-year, asset quality improves
